Source: ALL
Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 4771
Gene Symbol: NF2
NF2 		0.400 Biomarker disease CTD_human Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. 23334667 2013
Entrez Id: 5728
Gene Symbol: PTEN
PTEN 		0.400 Biomarker disease CTD_human A novel germline mutation of PTEN associated with brain tumours of multiple lineages. 12085208 2002
Entrez Id: 4771
Gene Symbol: NF2
NF2 		0.400 Biomarker disease HPO
Entrez Id: 5728
Gene Symbol: PTEN
PTEN 		0.400 CausalMutation disease CLINVAR
Entrez Id: 8314
Gene Symbol: BAP1
BAP1 		0.300 Biomarker disease CTD_human Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area. 25231345 2015
Entrez Id: 207
Gene Symbol: AKT1
AKT1 		0.300 Biomarker disease CTD_human Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. 23334667 2013
Entrez Id: 6608
Gene Symbol: SMO
SMO 		0.300 Biomarker disease CTD_human Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. 23334667 2013
Entrez Id: 8028
Gene Symbol: MLLT10
MLLT10 		0.300 Biomarker disease CTD_human Common variation at 10p12.31 near MLLT10 influences meningioma risk. 21804547 2011
Entrez Id: 5241
Gene Symbol: PGR
PGR 		0.300 Biomarker disease CTD_human Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors. 19747051 2010
Entrez Id: 1514
Gene Symbol: CTSL
CTSL 		0.300 Biomarker disease CTD_human Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors. 19747051 2010
Entrez Id: 1471
Gene Symbol: CST3
CST3 		0.300 Biomarker disease CTD_human Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors. 19747051 2010
Entrez Id: 1476
Gene Symbol: CSTB
CSTB 		0.300 Biomarker disease CTD_human Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors. 19747051 2010
Entrez Id: 3280
Gene Symbol: HES1
HES1 		0.300 Biomarker disease CTD_human Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. 21127729 2010
Entrez Id: 5241
Gene Symbol: PGR
PGR 		0.300 Biomarker disease CTD_human Regression of multiple intracranial meningiomas after cessation of long-term progesterone agonist therapy. 19731987 2010
Entrez Id: 210
Gene Symbol: ALAD
ALAD 		0.300 Biomarker disease CTD_human Delta-aminolevulinic acid dehydratase polymorphism and risk of brain tumors in adults. 16140629 2005
Entrez Id: 5241
Gene Symbol: PGR
PGR 		0.300 Biomarker disease CTD_human Sphenoid wing meningioma progression after placement of a subcutaneous progesterone agonist contraceptive implant. 8008172 1994
Entrez Id: 6598
Gene Symbol: SMARCB1
SMARCB1 		0.110 GeneticVariation disease BEFREE Clinical reports have described the occurrence of intracranial meningiomas in schwannomatosis patients and in families with germline SMARCB1 mutations. 23401320 2013
Entrez Id: 6598
Gene Symbol: SMARCB1
SMARCB1 		0.110 Biomarker disease HPO
Entrez Id: 51684
Gene Symbol: SUFU
SUFU 		0.100 Biomarker disease HPO
Entrez Id: 5155
Gene Symbol: PDGFB
PDGFB 		0.100 Biomarker disease HPO
Entrez Id: 472
Gene Symbol: ATM
ATM 		0.100 CausalMutation disease CLINVAR
Entrez Id: 4913
Gene Symbol: NTHL1
NTHL1 		0.100 CausalMutation disease CLINVAR
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA 		0.020 AlteredExpression disease BEFREE Paper I examines the VEGF-A protein and mRNA levels in 101 intracranial meningiomas. 23651727 2013
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA 		0.020 AlteredExpression disease BEFREE Vascular endothelial growth factor A protein level and gene expression in intracranial meningiomas with brain edema. 22085359 2011
Entrez Id: 6624
Gene Symbol: FSCN1
FSCN1 		0.010 AlteredExpression disease BEFREE We aimed to investigate the expression of E-cadherin and Fascin in a large number of meningioma specimens and determine if clinical and prognostic significance existsMETHODS: One hundred and thirty-four spinal and intracranial meningioma samples were collected. 31322546 2019